EARLY BIRD EXPIRES IN:

Days

Hours

Minutes

Seconds

 

EXCLUSIVE : NEW 2017 SPEAKERS INCLUDE:  

 

  • Erin Federman at World Biosimilar Congress
    Erin Federman
    Global Director - Team Lead
    Boehringer Ingelheim
    Francois Xavier Frapaise MD at World Biosimilar Congress
    Francois Xavier Frapaise MD
    CMO
    Merck Biosimilars
  • Adam Levysohn at World Biosimilar Congress
    Adam Levysohn
    Head of Global Market Access Biogen Biosimilars Business Unit
    Biogen
    Benedicte Lunddahl at World Biosimilar Congress
    Benedicte Lunddahl
    Head of Pharmacovigilance
    Danish Medicines Agency
  • Caroline Boulliat at World Biosimilar Congress
    Caroline Boulliat
    Immunology, Oncology. Biosimilar Business Unit Head
    Amgen Europe Gmbh
    Margaret Dolan at World Biosimilar Congress
    Margaret Dolan
    Regional Pharmacy Procurement Specialist
    N.H.S.
  • Ian Henshaw at World Biosimilar Congress
    Ian Henshaw
    Head of Business Operations
    Biogen
    Ber Oomen at World Biosimilar Congress
    Ber Oomen
    Executive Secretary and Treasurer
    ‎European Specialist Nurses Organisations
  • Ingrid Schwarzenberger at World Biosimilar Congress
    Ingrid Schwarzenberger
    Head of Global Regulatory Affairs Biopharmaceuticals
    Sandoz Biopharmaceuticals Gmbh
    Elena Wolff-Holz at World Biosimilar Congress
    Elena Wolff-Holz
    Elena Wolff-Holz, Chair, Biosimilar Medicinal Products Working Party (BMWP)
    Paul Ehrlich Institut

 

2017 ADVISORY BOARD 

Alain Beck

Alain Beck
Senior Director Analytical Chemistry, CIPF and Associate Editor
mAbs 

 

Uwe Gudat
Head of Safety, Biosimilars
 Merck

 

Cecil Nick

Cecil Nick
Vice President, Biotechnology
PAREXEL

 

Paul Chrisp

Paul Chrisp
Programme Director, Medicines and Prescribing Center
 NICE


Ingrid

Ingrid Schwarzenberger
Head Global Regulatory Affairs
Sandoz Biopharmaceuticals 

Steiner Marsden Steinar MadsenSteinar Madsen
Medical Director, Department of Drug Information
Norwegian Medicines Agency

 

DOWNLOAD THE BROCHURE

gianluca

Gianluca Trifirò
Assistant Professor of Pharmacology
Erasmus Medical Center

WHAT IS THE WORLD BIOSIMILAR CONGRESS?

 

CONFERENCE

NETWORKING 

Biosimilar 2016 panel discussion

The World Biosimilar Congress is a commercially focused event bringing together the full value chain and located in one of the world’s major life science hubs, Basel. Consisting of thought-leaders from across the globe, the World Biosimilar Congress looks at commercialising and pushing forward the adoption of biosimilars globally. Over the last 5 years, the Congress has built up a reputation for delivering high level content and bringing together the senior executives from sourcing through to patient. It is co-located with the European Antibody Congress, World Immunotherapy Congress, and HPAPI World Congress.

Biosimilar 2016 panel discussion

The World Biosimilar Congress recognises the importance of networking and offers an experience which allows you to do just that. With a series of round table discussions, speed networking, networking drinks receptions, breaks and lunches, we provide you with plenty of opportunities to have those all important conversations. With multiple networking formats we enable you to have casual chats and introductions without compromising your time attending the conference sessions.

 

DOWNLOAD THE BROCHURE

TRACK 1 

* New* Track 1: Market access strategies, opportunities and commercial challenges 

  • Updates on biosimilar and biobetter regulatory guidelines

  • Streamlining approval and access for follow-on biologics

  • Opportunities and challenges in bringing future  biosimilars to market

  • Emerging markets and the establishment of biosimilar products

  • Technology transfer strategies for market access

  • Successful biosimilar product case studies from benchtop to market

TRACK 2

Track 2: Biosimilar and Biobetter development 

  • Biosimilar and biobetter development and clinical case studies

  • Designing and conducting global clinical trials

  • Designing clinical models and using data to effectively demonstrate biosimilarity

  • Opportunities in biobetters development

  • The latest on demonstrating interchangeability

  • Approaches to harmonizing immunogenicity testing

  • Novel techniques and technologies for characterisation, assay development and extrapolation

  • *New* Pharmacovigilence (side effects) and innovative clinical trials 

 

bioismilar prospectus 2017

 


PUT YOUR COMPANY AT THE FOREFRONT OF THE BIOSIMILAR INDUSTRY

 

Download the prospectus to find out different ways you can get involved in the most important biosimilar meeting in europe.

 

DOWNLOAD PROSPECTUS

 

"This is an excellent strategic conference on the global development of biosimilars and should be attended by anyone developing biosimilars."


N.D.A. Regulatory Science Ltd

col-md-1

WHO ATTENDS?

 

Bayer Pharma AG G.E Helthcare Janssen Takeda Express Scripts Inc Merck Bio Rad Laboratories Cellitron Terumo  Europa Bioproducts Amgen Sandoz Biogen PAREXEL Merck Millipore Boehringer Ingelheim Abbvie Ag Quintiles  Alexion Pharma Pfizer Roche Myoderm Fujifilm Kyowa Kirin Biologics Alliance for Safe Biologic Medicines NDA Group Sterne Kessler Goldstein And Fox Plc Prozyme  Cinfa Biotech  ExcellGene Orion Pharma Altran Deallus  Prozyme   A.L.S. Automated Lab Solutions Resindion srl McKinsey & Company Genzyme IMS Health MSPharma Daiichi Sankyo INC Research Hospira R-Pharm ProBioGen  Novo Nordisk Pharmatech Bionical Ltd Alvotech Wyatt Health Management Promogen-MAB BioXpress Therapeutics Dr. Reddy's Laboratories SA University of Oslo  Asterand Avrentim Johnson and Johnson Probiomed  Vantage Health Hoffman La Roche  Probiomed  MedImmune InSight Biopharmaceuticals

col-md

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Partner with the world biosimilar congress:

Forge new partnerships

generate new leads

build your brand presence

 

DOWNLOAD PROSPECTUS

"Great conference. Great planning, execution and very responsive throughout the process."

 

Executive Director - Global Colon Cancer Association